secwatch / observer
8-K filed May 8, 2023, 7:59 PM ET ticker FRPT CIK 0001611647
earnings confidence high sentiment positive materiality 0.75

Freshpet Q1 net sales up 26.7% to $167.5M; Adjusted EBITDA turns positive at $3.0M

Freshpet, Inc.

2023-Q1 EPS reported -$0.52 revenue$167,522,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Freshpet, Inc. reported for its first quarter ended March 31, 2023 results: revenue Net sales of $167.5 million, net income Net loss of $24.8 million. Guidance reaffirmed.

Period
for its first quarter ended March 31, 2023
Revenue
Net sales of $167.5 million
Net income
Net loss of $24.8 million
Guidance
reaffirmed
Result
reported results
Exact text from the filing
(Nasdaq: FRPT) today reported financial results for its first quarter ended March 31, 2023 . First Quarter 2023 Financial Highlights Compared to Prior Year Period ● Net sales of $167.5 million, an increase of 26.7% ● Net loss of $24.8 million, compared with prior year net loss of $17.5 million ● Adjusted EBITDA of $3.0 million, compared to prior year of $(0.3) million.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Freshpet, Inc. reported For full year 2023 results: revenue Net sales of ~$750 million. Guidance reaffirmed.

Period
For full year 2023
Revenue
Net sales of ~$750 million
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
For full year 2023, the Company reiterates its full year underlying guidance on Net Sales and Adjusted EBITDA. The Company expects the following results: ● Net sales of ~$750 million, an increase of ~26% from 2022. ● Adjusted EBITDA of at least $50 million.
View on SEC.gov

Browse all earnings releases →

Freshpet, Inc. filing history →

Source: SEC EDGAR
accession 0001437749-23-012894
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.